News | PET Imaging | June 16, 2021

New PET Tracer Detects Hallmark of Alzheimer’s Disease Years Before Symptoms Emerge

A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed.

Figure 1. Tau accumulation over one year measured in composite A) mesial temporal ROI; and B) temporoparietal ROI in cognitively unimpaired participants (blue) and cognitively impaired participants (red). The CI group included participants with clinical mild cognitive impairment and dementia. Higher rates of tau accumulation were observed in participants on the AD continuum (CU Aβ+ve and CI Aβ+ve). Participants with the highest baseline tau and rates of tau accumulation were younger and more likely to be CI Aβ+ve. Image courtesy of SNMMI

June 16, 2021 — A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed. With the potential to measure increases in tau over a long period of time, this tracer offers an important tool to assess the effectiveness of Alzheimer’s disease treatments in clinical trials. This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.

Tau is a protein commonly found in healthy brain neurons. In people with certain brain disorders, like Alzheimer’s disease, chemical changes cause tau proteins to accumulate in various parts of the brain. As such, tau is valuable as a biomarker for measuring disease progression.

In the study, researchers sought to detect patterns and rates of tau accumulation in both a cognitively normal aging population and in those with Alzheimer’s disease. PET imaging with the novel radiotracer 18F-MK6240 was performed on all participants at baseline and after 12 months. After each scan, uptake of the radiotracer was measured in multiple areas of the brain.

Increases in tau were measured in both participant groups and longitudinal tau imaging was effective in discriminating between the two cohorts. The uptake of 18F-MK6240 was higher at baseline and after one year in participants who were on the Alzheimer’s disease continuum in comparison to the cognitively normal aging participants.

“The effectiveness of the 18F-MK6240 tracer is important for drug trials that aim to measure whether or not treatments to remove tau from the brain are actually working,” said Christopher Rowe, BMBS, FRACP, MD, FAANMS, director of molecular imaging research at Austin Health and director of the Australian Dementia Network in Melbourne, Australia. “Use of the radiotracer will allow researchers to select people at different stages of Alzheimer’s disease for clinical trials, which ultimately may speed the development of effective treatments for the disease.”

For more information: www.snmmi.org

More news from SNMMI21 can be found here

Related Alzheimers' content:

VIDEO: Researchers Use MRI to Predict Alzheimer's Disease

Brain Iron Accumulation Linked to Cognitive Decline in Alzheimer's Patients

Good Results for Alzheimer’s Imaging Agent

NIH Augments Large Scale Study of Alzheimer’s Disease Biomarkers

Alzheimer’s Association Launches New Website for IDEAS Study

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

New Super-resolution Technique Allows for More Detailed Brain Imaging

Related Content

The FLASH Effect significantly improves the therapeutic ratio for curing cancer

The FLASH Effect significantly improves the therapeutic ratio for curing cancer

News | Radiation Oncology | July 28, 2021
July 28, 2021 — IntraOp Medical Corporation announced that ...
Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly and Annual Meeting, the world’s largest annual radiology forum, to be held at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | July 21, 2021
July 21, 2021 — Registration is now open for the Radiological Society of North America (...

Positrigo founders Max Ahnen, Ph.D. (left) and Jannis Fischer, Ph.D.

News | PET Imaging | July 16, 2021
A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-high sensitivity that supports excellent spatial resolution and image quality. Given the long axial field of view (AFOV) of the uEXPLORER, study authors have proposed new, extended measurements for phantoms to characterize total-body PET imaging more appropriately. This research was published in the June issue of The Journal of Nuclear Medicine.

Human imaging examples of performance of uEXPLORER total-body PET scanner. (A) Axial slice from 18F-fluciclovine PET image (right), with corresponding fused image (middle) and CT image (left), of 68-y-old patient with castration-resistant metastatic prostate cancer, demonstrating clear visualization of 18F-flucicovine accumulation within 2.5-mm-diameter pulmonary nodule. (B) Maximum-intensity projection of representative clinical oncology 18F-FDG PET scan reconstructed with 20-, 5-, and 2.5-min durations, of 59-y-old patient with lung cancer. Images show primary tumor in left lower lobe of lung (dashed circle), with multiple variable-sized (0.8-6 cm) hilar, mediastinal, and lower esophageal nodal metastases (arrows) and ~1-cm 18FFDG-avid left adrenal nodule (arrowhead), which is visualized for all scan durations. Image created by Y. Abdelhafez and B.A. Spencer, EXPLORER Molecular Imaging Center, UC Davis, Sacramento, CA

News | PET Imaging | July 10, 2021
July 10, 2021 — A performance evaluation of the uEXPLORER total-body PET/CT scanner showed that it exhibits ultra-hig
American Society for Radiation Oncology (ASTRO) to host in-person Annual Meeting in Chicago, October 24-27

Getty Images

News | ASTRO | July 08, 2021
July 8, 2021 — Registration opens today for the American Society for Radiation Oncology's (...
Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia

Getty Images

News | PET Imaging | July 08, 2021
July 8, 2021 — Biogen and...
The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.

Image courtesy of JNM

News | PET Imaging | June 28, 2021
June 28, 2021 — The U.S.